Summary
Global Markets Direct’s, ‘Orexin Receptor Type 1 (Ox-1-R or Ox1R or Hypocretin Receptor Type 1 or HCRTR1) - Pipeline Review, H1 2016’, provides in depth analysis on Orexin Receptor Type 1 (Ox-1-R or Ox1R or Hypocretin Receptor Type 1 or HCRTR1) targeted pipeline therapeutics.
The report provides comprehensive information on the Orexin Receptor Type 1 (Ox-1-R or Ox1R or Hypocretin Receptor Type 1 or HCRTR1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Orexin Receptor Type 1 (Ox-1-R or Ox1R or Hypocretin Receptor Type 1 or HCRTR1) targeted therapeutics development and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Orexin Receptor Type 1 (Ox-1-R or Ox1R or Hypocretin Receptor Type 1 or HCRTR1)
- The report reviews Orexin Receptor Type 1 (Ox-1-R or Ox1R or Hypocretin Receptor Type 1 or HCRTR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Orexin Receptor Type 1 (Ox-1-R or Ox1R or Hypocretin Receptor Type 1 or HCRTR1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Orexin Receptor Type 1 (Ox-1-R or Ox1R or Hypocretin Receptor Type 1 or HCRTR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Orexin Receptor Type 1 (Ox-1-R or Ox1R or Hypocretin Receptor Type 1 or HCRTR1) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Orexin Receptor Type 1 (Ox-1-R or Ox1R or Hypocretin Receptor Type 1 or HCRTR1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Orexin Receptor Type 1 (Ox-1-R or Ox1R or Hypocretin Receptor Type 1 or HCRTR1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Companies Mentioned
C4X Discovery Holdings PLC
Eisai Co., Ltd.
Hager Biosciences, LLC
Heptares Therapeutics Limited
Merck & Co., Inc.
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Orexin Receptor Type 1 (Ox-1-R or Ox1R or Hypocretin Receptor Type 1 or HCRTR1) Overview 6
Therapeutics Development 7
Orexin Receptor Type 1 (Ox-1-R or Ox1R or Hypocretin Receptor Type 1 or HCRTR1) - Products under Development by Stage of Development 7
Orexin Receptor Type 1 (Ox-1-R or Ox1R or Hypocretin Receptor Type 1 or HCRTR1) - Products under Development by Therapy Area 8
Orexin Receptor Type 1 (Ox-1-R or Ox1R or Hypocretin Receptor Type 1 or HCRTR1) - Products under Development by Indication 9
Orexin Receptor Type 1 (Ox-1-R or Ox1R or Hypocretin Receptor Type 1 or HCRTR1) - Pipeline Products Glance 10
Late Stage Products 10
Early Stage Products 11
Orexin Receptor Type 1 (Ox-1-R or Ox1R or Hypocretin Receptor Type 1 or HCRTR1) - Products under Development by Companies 12
Orexin Receptor Type 1 (Ox-1-R or Ox1R or Hypocretin Receptor Type 1 or HCRTR1) - Therapeutics Assessment 14
Assessment by Monotherapy/Combination Products 14
Assessment by Mechanism of Action 15
Assessment by Route of Administration 16
Assessment by Molecule Type 17
Orexin Receptor Type 1 (Ox-1-R or Ox1R or Hypocretin Receptor Type 1 or HCRTR1) - Companies Involved in Therapeutics Development 18
C4X Discovery Holdings PLC 18
Eisai Co., Ltd. 19
Hager Biosciences, LLC 20
Heptares Therapeutics Limited 21
Merck & Co., Inc. 22
Orexin Receptor Type 1 (Ox-1-R or Ox1R or Hypocretin Receptor Type 1 or HCRTR1) - Drug Profiles 23
DORA-12 - Drug Profile 23
Product Description 23
Mechanism Of Action 23
R&D Progress 23
EORA-101 - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
HTL-6641 - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
lemborexant - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
Small Molecule to Antagonize Orexin 1 for Central Nervous System Disorders - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
Small Molecules to Antagonize CRF-R1 and OREXIN-1 for Nicotine Addiction - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
Small Molecules to Antagonize Orexin-1 Receptor for Addiction - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
Small Molecules to Antagonize Orexin-1 Receptor for CNS Disorders - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
Orexin Receptor Type 1 (Ox-1-R or Ox1R or Hypocretin Receptor Type 1 or HCRTR1) - Dormant Projects 32
Orexin Receptor Type 1 (Ox-1-R or Ox1R or Hypocretin Receptor Type 1 or HCRTR1) - Discontinued Products 33
Orexin Receptor Type 1 (Ox-1-R or Ox1R or Hypocretin Receptor Type 1 or HCRTR1) - Featured News & Press Releases 34
May 20, 2015: Selection of drug candidate from Orexin-1 programme to treat stress-related addictive disorders and entry into pre-clinical development 34
Feb 03, 2015: Merck’s Insomnia Medicine BELSOMRA (suvorexant) C-IV, the First and Only Orexin Receptor Antagonist, Now Available in the United States 34
Dec 10, 2014: Eisai Demonstrates Efficacy Of Investigational Dual Orexin Receptor Antagonist E2006 In Sleep Initiation And Maintenance 35
Nov 26, 2014: Merck announces launch of Berusomura tablets15mg/20mg in Japan 36
Aug 13, 2014: FDA Approves BELSOMRA for the Treatment of Insomnia 36
Jul 01, 2013: Merck Receives Complete Response Letter for Suvorexant, Merck’s Investigational Medicine for Insomnia 38
May 22, 2013: Merck Wins FDA Panel Recommendation For Insomnia Drug Suvorexant At Lower Dose 39
May 20, 2013: Merck's Experimental Insomnia Drug Safe But May Carry Troublesome Side Effects, FDA Staff Says 39
Apr 03, 2013: Merck's Insomnia Drug Suvorexant Induces Sleep With Fewer Side Effects, Preclinical Study Shows 40
Nov 28, 2012: New Drug May Offer New Approach To Treating Insomnia, Study Finds 40
Nov 08, 2012: Merck Announces FDA Acceptance Of New Drug Application For Suvorexant 41
Sep 10, 2012: Merck Announces New Phase III Data For Investigational Insomnia Medicine Suvorexant 41
Jun 13, 2012: Merck Announces New Positive Data From Two Pivotal Phase III Efficacy Trials Of Suvorexant For Treatment Of Insomnia 43
Feb 06, 2012: Merck Provides Update On Development Program For Investigational Insomnia Drug, Suvorexant 45
Jun 09, 2010: Merck Announces Phase IIb Study Results Of Investigational Insomnia Therapy Drug MK-4305 45
Appendix 48
Methodology 48
Coverage 48
Secondary Research 48
Primary Research 48
Expert Panel Validation 48
Contact Us 48
Disclaimer 49
List of Tables
Number of Products under Development for, H1 2016 7
Number of Products under Development by Therapy Area, H1 2016 8
Number of Products under Development by Indication, H1 2016 9
Comparative Analysis by Late Stage Development, H1 2016 10
Comparative Analysis by Early Stage Products, H1 2016 11
Number of Products under Development by Companies, H1 2016 12
Products under Development by Companies, H1 2016 13
Assessment by Monotherapy/Combination Products, H1 2016 14
Number of Products by Stage and Mechanism of Action, H1 2016 15
Number of Products by Stage and Route of Administration, H1 2016 16
Number of Products by Stage and Molecule Type, H1 2016 17
Pipeline by C4X Discovery Holdings PLC, H1 2016 18
Pipeline by Eisai Co., Ltd., H1 2016 19
Pipeline by Hager Biosciences, LLC, H1 2016 20
Pipeline by Heptares Therapeutics Limited, H1 2016 21
Pipeline by Merck & Co., Inc., H1 2016 22
Dormant Projects, H1 2016 32
Discontinued Products, H1 2016 33
List of Figures
Number of Products under Development for, H1 2016 7
Number of Products under Development by Top 10 Indication, H1 2016 9
Comparative Analysis by Early Stage Products, H1 2016 11
Assessment by Monotherapy/Combination Products, H1 2016 14
Number of Products by Stage and Mechanism of Actions, H1 2016 15
Number of Products by Stage and Routes of Administration, H1 2016 16
Number of Products by Stage and Molecule Type, H1 2016 17
